For the latest COVID-19 (Coronavirus) information: CCTG public updates | CCTG member information

Planned EDC/Rave Upgrade

Starting Sunday, March 29th, 2020 beginning at 8:00 AM EDT, and ending on Sunday, March 29th, 2020 beginning at 12:30 AM EDT. During this time there will be no access to the EDC/Rave system. Please share this notification to the personnel who will be affected by this within your organization. Maintenance Start: Sunday, March 29th, 2020 at 8:00 AM EDT. Maintenance End: Sunday, March 29th, 2020 at 12:30 AM EDT.
We are sorry for any inconvenience this may cause.

An interview with Senior Investigator Annette Hay

Accrual barriers and detection of early toxicity signal in older, less-fit patients
Wednesday, January 8, 2020
An interview with Senior Investigator Annette Hay

Prof Annette Hay speaks to ecancer at the ASH 2019 meeting in Orlando about accrual barriers and detection of early toxicity signal in older, less-fit patients treated with azacitidine and nivolumab for newly diagnosed acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Prof Hay says that AML and MDS are typically diseases of older people, yet these patients are poorly represented in clinical trials. This trial deliberately accrued older patients using broad enrolment criteria with the aim of improving outcomes in this patient population.

See the interview here: https://ecancer.org/en/video/8495-azacitidine-plus-nivolumab-in-older-adults-with-aml-or-mds